|Bid||23.03 x 1200|
|Ask||23.07 x 900|
|Day's Range||22.70 - 23.81|
|52 Week Range||21.67 - 27.72|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Details the CEO buys this past week from the following companies: Allogene Therapeutics, Conagra Brands, Texas Capital Bancshares, Fastenal and CymaBay Therapeutics
President and CEO of Allogene Therapeutics Inc (NASDAQ:ALLO) David D Chang bought 40,000 shares of ALLO on 10/15/2018 at an average price of $18 a share.
Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, today announced the closing of its previously announced initial public offering of 20,700,000 shares of its common stock, which includes 2,700,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a ...
Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, rang the opening bell at the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market. Allogene, with headquarters in South San Francisco, is led by a world-class management team with significant experience in cell therapy. Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably, at greater scale, and to more patients.
Allogene Therapeutics is set to begin trading on the Nasdaq Stock Exchange under the ticker symbol “ALLO.” The stock is expected to debut Thursday, Oct. 11, although an official IPO date has not yet been ...